Robert Janssen
9Patents
2h-index
30Co-inventors
47Inventor score
Filing activity: Jan 31, 2007 → Jun 29, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9044509B2 | Inhibition of HIV infection through chemoprophylaxis | Human Necessities | 5 | Active |
| US10751412B2 | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer | Chemistry; Metallurgy | 3 | Active |
| US9579333B2 | Inhibition of HIV infection through chemoprophyalxis | Human Necessities | 2 | Active |
| US9937191B2 | Inhibition of HIV infection through chemoprophylaxis | Human Necessities | 2 | Active |
| US10335423B2 | Inhibition of HIV infection through chemoprophylaxis | Human Necessities | 1 | Active |
| US11684669B2 | CpG-adjuvanted SARS-CoV-2 virus vaccine | Emerging Cross-Sectional Technologies | 1 | Active |
| US12364745B2 | Immunogenicity of a CpG-adjuvanted recombinant plague vaccine | Emerging Cross-Sectional Technologies | 0 | Active |
| US12296002B2 | Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | Chemistry; Metallurgy | 0 | Active |
| US11918648B2 | Combination of a PD-1 antagonist and CpG-C type oligonucleotide for treating cancer | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.